

# **EXHIBIT**

**44**

1 IN THE SUPERIOR COURT  
2 OF THE STATE OF DELAWARE  
3 IN AND FOR NEW CASTLE COUNTY

4 IN RE:  
5 SEROQUEL LITIGATION : MDL NO. 1769

6 :  
7 THIS DOCUMENT RELATES:  
8 TO ALL ACTIONS :

-----  
9 IN RE: : SUPERIOR COURT  
10 RISPERDAL/SEROQUEL/ : OF NEW JERSEY  
11 ZYPREXA LITIGATION : LAW DIVISION  
12 : MIDDLESEX COUNTY  
13 : CASE NO. 274

-----  
14 AIMEE DANIELS, : IN THE CIRCUIT  
15 : COURT OF THE  
16 V. : COUNTY OF ST. LOUIS  
17 : STATE OF  
18 ASTRAZENECA : MISSOURI  
19 PHARMACEUTICALS, L.P. : 05CC-004759  
20 ET AL. : DIVISION 6

-----  
21 SANTOS MALDANADO, : IN THE CIRCUIT  
22 minor, by and through: COURT OF THE  
23 his natural mother : COUNTY OF ST. LOUIS  
24 and next friend, : STATE OF  
LOUISE WILSON : MISSOURI  
V. : 06CC-003930  
JANSSEN PHARMACEUTICA: DIVISION 6  
L.P., ET AL. :

25 - - -  
26 May 10, 2007

27 - - -  
28 C O N F I D E N T I A L  
29 - - -

30 30(b)(6) deposition of ASTRAZENECA  
31 PHARMACEUTICALS, L.P., by and through JON  
32 DOWLING.

33 - - -  
34 Golkow Technologies, Inc.  
Suite 760  
1880 John F. Kennedy Boulevard  
Philadelphia, Pennsylvania 19103  
877.370.3377

1 LENA BARNETT, minor, : IN THE CIRCUIT  
 by and through her : COURT OF THE  
 2 natural mother and : COUNTY OF ST. LOUIS  
 next friend, : STATE OF  
 3 MARY BARNETT : MISSOURI  
 V. : 06CC-000333  
 4 JANSSEN PHARMACEUTICA: DIVISION 6  
 L.P., ET. AL. :  
 5 -----  
 6 LOIS BAER, as : IN THE CIRCUIT  
 Representative of the: COURT OF THE  
 Estate of MATTHEW : COUNTY OF ST. LOUIS  
 7 BAER, Deceased : STATE OF  
 V. : MISSOURI  
 8 JANSSEN PHARMACEUTICA: 06CC-002401  
 L.P., ET. AL. : DIVISION 6  
 9 -----  
 10 TERRY STRINGER : IN THE CIRCUIT  
 : COURT OF THE  
 11 V. : COUNTY OF ST. LOUIS  
 : STATE OF  
 JANSSEN PHARMACEUTICA: MISSOURI  
 12 L.P., ET. AL. : 06CC-002173  
 : DIVISION 6  
 13 -----  
 14 STEPHEN ROSAS : IN THE CIRCUIT  
 : COURT OF THE  
 15 V. : COUNTY OF ST. LOUIS  
 : STATE OF  
 16 ASTRAZENECA : MISSOURI  
 PHARMACEUTICALS, : 05CC-004755  
 L.P., ET.AL. : DIVISION 6  
 17 -----  
 18 PAMELA MOORE, : IN THE CIRCUIT  
 : COURT OF THE  
 19 V. : COUNTY OF ST. LOUIS  
 : STATE OF  
 JANSSEN PHARMACEUTICA: MISSOURI  
 20 L.P., ET. AL. : 05CC-006375  
 : DIVISION 6  
 21 -----  
 22  
 23  
 24

1 KATHRYN SCHULTZ, : SUPERIOR COURT OF  
 ET. AL. : THE STATE OF  
 2 : CALIFORNIA IN AND  
 V. : FOR THE COUNTY OF  
 3 : SAN FRANCISCO  
 ASTRAZENECA : CGC-06-453676  
 4 PHARMACEUTICALS, :  
 L.P., ET.AL. :  
 5 -----  
 6  
 7 30(b)(6) deposition of ASTRAZENECA  
 8 PHARMACEUTICALS, L.P., by and through JON  
 9 DOWLING, taken pursuant to notice, was  
 10 held at the Four Season Hotel,  
 11 Philadelphia, Pennsylvania, commencing at  
 12 9:00 a.m., on the above date, before  
 13 Linda Rossi Rios, RPR, CSR and Notary  
 14 Public.  
 15 - - -  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24

1 APPEARANCES:  
 2  
 3 AYLSTOCK, WITKIN & SASSER, PLC  
 BY: KENNETH W. SMITH, ESQUIRE  
 4 4400 Bayou Boulevard, Suite 58  
 Pensacola, Florida 32503-2673  
 5 850-916-7450  
 ksmith@aws-law.com  
 6 Representing Plaintiffs in New  
 Jersey and Delaware  
 7  
 8 SHELLER LUDWIG & SHELLER, PC  
 BY: THOMAS E. MELLON, III, ESQUIRE  
 9 3rd Floor  
 1528 Walnut Street  
 10 Philadelphia, Pennsylvania 19102  
 215-790-7300  
 11 tmellon@sheller.com  
 Representing Plaintiffs in New  
 12 Jersey  
 13  
 14 DECHERT LLP  
 BY: BRENNAN J. TORREGROSSA, ESQUIRE  
 and  
 15 BY: A. ELIZABETH BALAKHANI, ESQUIRE  
 Cira Centre, 2929 Arch Street  
 16 Philadelphia, Pennsylvania 19104  
 215-994-2358  
 215-994-2487  
 17 brennan.torregrossa@dechert.com  
 18 elizabeth.balakhani@dechert.com  
 Representing AstraZeneca  
 19  
 20  
 21  
 22  
 23  
 24

1 APPEARANCES:  
 2  
 3 PEPPER HAMILTON LLP  
 BY: ALLYSON BACCINI, ESQUIRE  
 4 3000 Two Logan Square  
 18th and Arch Streets  
 Philadelphia, Pennsylvania 19103  
 5 215-981-4781  
 baccinia@pepperlaw.com  
 6 Representing Eli Lilly & Company  
 7  
 8 ALSO PRESENT:  
 9 BAILEY PERRIN BAILEY  
 RHONDA RADLIFF  
 PROJECT MANAGEMENT  
 10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24

1 - - -  
 2 I N D E X  
 3 - - -  
 4  
 5 Testimony of: JON DOWLING  
 6 By Mr. Smith 284  
 7  
 8 - - -  
 9 E X H I B I T S  
 10 - - -  
 11  
 12 NO. DESCRIPTION PAGE  
 13 Dowling-3 Cross-Notices 409  
 14  
 15  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24

1 (It is hereby stipulated and  
 2 agreed by and between counsel that  
 3 sealing, filing and certification  
 4 are waived; and that all  
 5 objections, except as to the form  
 6 of questions, be reserved until  
 7 the time of trial.)  
 8 - - -  
 9 JON DOWLING, after having  
 10 been previously sworn, was  
 11 examined and testified as follows:  
 12 - - -  
 13 MR. TORREGROSSA: I took a  
 14 look at the protective  
 15 stipulation, and I think it is  
 16 within my right, and I've  
 17 rethought my position here, to  
 18 designate the entire transcript  
 19 confidential.  
 20 It also asks me to ask you,  
 21 the court reporter, to please  
 22 designate the legend as  
 23 confidential on all copies of the  
 24 original.

1 - - -  
 2 DEPOSITION SUPPORT INDEX  
 3 - - -  
 4  
 5 Direction to Witness Not to Answer  
 6 Page Line Page Line Page Line  
 7 None  
 8  
 9  
 10 Request for Production of Documents  
 11 Page Line Page Line Page Line  
 12 None  
 13  
 14  
 15 Stipulations  
 16 Page Line Page Line Page Line  
 17 283 1  
 18  
 19  
 20 Question Marked  
 21 Page Line Page Line Page Line  
 22 None  
 23  
 24

1 MR. SMITH: We object.  
 2 MR. TORREGROSSA: I knew you  
 3 would. That's something we'll  
 4 have to sort out later.  
 5 - - -  
 6 EXAMINATION  
 7 - - -  
 8 BY MR. SMITH:  
 9 Q. Mr. Dowling, good morning.  
 10 A. Good morning.  
 11 Q. You are still under oath.  
 12 A. Yes, I am.  
 13 Q. Have you spoken with anybody  
 14 since we last met concerning the subject  
 15 matter of this deposition?  
 16 MR. TORREGROSSA: That's a  
 17 yes or no.  
 18 THE WITNESS: No.  
 19 BY MR. SMITH:  
 20 Q. Let's turn to ICON and talk  
 21 about that to start off this morning.  
 22 What is ICON?  
 23 A. ICON is the predecessor to  
 24 the MACS system.

1 Q. Is that a system that you  
2 managed?

3 A. It is not a system that I  
4 managed.

5 Q. Is it a system that your  
6 department managed?

7 A. Yes, it is, in some way.

8 Q. Your department provided  
9 support to the users?

10 A. Yes, the IS department did.

11 Q. In some way, what do you  
12 mean?

13 A. I mean as my department is  
14 organized today, no. But a predecessor  
15 organization did.

16 Q. How was your department  
17 organized in its previous life?

18 A. Today we support all of  
19 Commercial and previously there was  
20 somewhat of a separation between the  
21 sales or the marketing side application  
22 center.

23 Q. Separated from?

24 A. Meaning the IS groups, we

1 systems that are listed in the notice are  
2 not supported by your department at all?

3 A. No, I did say NICE when I  
4 said that list, correct?

5 Q. If you didn't, we'll accept  
6 it now.

7 MR. TORREGROSSA: So  
8 amended.

9 THE WITNESS: Yes, those are  
10 the ones supported by my  
11 department.

12 BY MR. SMITH:

13 Q. And Mr. Draper is not in  
14 your department?

15 A. No, he is not.

16 Q. And his department is what?

17 A. I believe his area is called  
18 GDDIS. I know you're going to ask.  
19 Global Drug Development IS.

20 Q. When was your department  
21 reorganized to its current configuration?

22 A. It was effective January 1,  
23 2006.

24 Q. And prior to January 1,

1 worked together, but we were still -- the  
2 structure was different than it is today  
3 in terms of who was responsible for the  
4 applications.

5 Q. Probably a better way to do  
6 this might be to take a moment and make  
7 sure we understand how your department is  
8 organized today. What applications and  
9 databases is your department responsible  
10 for today?

11 A. The list that we talked  
12 about yesterday. My group is responsible  
13 for Touchstone, Compass, NICE, MACS,  
14 KNOWBOL. ICON is on there, it's a  
15 legacy, it would be our group's  
16 responsibility for the information there  
17 as the transition came to our group.  
18 SnapPharma, ViewPoint, LectureBureau  
19 Express, PREP and Northstar.

20 MR. TORREGROSSA: For the  
21 record, the list he's talking  
22 about is the 30(b)(6) notice.

23 BY MR. SMITH:

24 Q. Now, the other databases or

1 2006, what department would have been  
2 responsible for providing support for the  
3 ICON system?

4 A. BIS Marketing, Business  
5 Information Services Marketing.

6 Q. What other databases or  
7 systems were included or supported by BIS  
8 Marketing?

9 A. The data warehouse. The Web  
10 sites. KNOWBOL, MACS, ViewPoint. Those  
11 were the ones.

12 Q. And what were the other --  
13 prior to 2006, what were the other IS  
14 departments?

15 A. With us, we were called BIS  
16 Sales. That's where I was.

17 Q. So there were just -- BIS  
18 had two divisions, one was Marketing  
19 Business Information and the other was  
20 Sales?

21 A. That's the ones that made up  
22 what we are now called, CISS, Commercial  
23 Information Services and Solutions.

24 Q. So which databases or

1 systems were supported by your division,  
 2 which was BIS Sales. Right?  
 3 A. BIS Sales would have been  
 4 Compass, LB Express, PREP, Northstar.  
 5 SnapPharma would have been housed in --  
 6 the data we had would have been housed by  
 7 BIS Sales.  
 8 Q. The data would have been  
 9 housed by BIS Sales?  
 10 A. Yes.  
 11 Q. Is that different from  
 12 providing support for the system?  
 13 A. Yes, it didn't exist.  
 14 Q. Okay. Because it was a  
 15 legacy system?  
 16 A. Like ICON, it's a legacy  
 17 system. It's my responsibility for the  
 18 legacy information now.  
 19 Q. When you say "legacy  
 20 system," exactly what do you mean by  
 21 that?  
 22 A. It means the system was  
 23 operated and no longer is in operation.  
 24 Q. But you retained -- the

1 company's policy would be to retain the  
 2 data that was in the system. Right?  
 3 MR. TORREGROSSA: Objection  
 4 to form and scope. He's not here  
 5 to talk about retaining the data  
 6 from a litigation perspective. He  
 7 can comment with respect to  
 8 business purposes.  
 9 MR. SMITH: I didn't say  
 10 litigation. The notice says  
 11 retention.  
 12 MR. TORREGROSSA: I  
 13 understand that.  
 14 MR. SMITH: And that's what  
 15 I asked him about.  
 16 MR. TORREGROSSA: And he can  
 17 answer on behalf of his group and  
 18 the business policies for  
 19 retention, but not litigation.  
 20 Do you understand the  
 21 instruction?  
 22 THE WITNESS: Yes.  
 23 MR. TORREGROSSA: Do you  
 24 want the question read back or do

1 you want to rephrase?  
 2 BY MR. SMITH:  
 3 Q. I want to know what the  
 4 retention policies of AstraZeneca were --  
 5 what the retention policies of  
 6 AstraZeneca are today with regard to  
 7 these legacy systems?  
 8 MR. TORREGROSSA: And  
 9 objection, scope, privilege, work  
 10 product. You can answer so long  
 11 as you answer with respect to the  
 12 retention policies of your group  
 13 and the company, not the  
 14 litigation perspective.  
 15 THE WITNESS: The retention  
 16 policies for data, AstraZeneca, is  
 17 active life, useful life of the  
 18 information. If it's not active  
 19 life, it does not have to be  
 20 retained.  
 21 BY MR. SMITH:  
 22 Q. How would you describe or  
 23 define "active life"?  
 24 A. Based on the business' need

1 for that information.  
 2 Q. Who would make that  
 3 determination as to whether it was needed  
 4 for the business or not?  
 5 A. The business units that  
 6 would own that system.  
 7 Q. Has any of the data from  
 8 these systems that we mentioned this  
 9 morning been lost or destroyed?  
 10 MR. TORREGROSSA: Objection.  
 11 Compound.  
 12 BY MR. SMITH:  
 13 Q. You can answer.  
 14 A. We talked about SnapPharma  
 15 yesterday.  
 16 Q. Some of the data in 1998?  
 17 A. Yes.  
 18 Q. I recall that. Other than  
 19 that?  
 20 A. To my knowledge, I do not  
 21 believe any information would have been  
 22 lost and/or not available in archive.  
 23 Q. So a slightly different  
 24 question. Does the data still exist

1 today in some form?  
2 MR. TORREGROSSA: Objection  
3 to form.  
4 BY MR. SMITH:  
5 Q. In other words --  
6 A. Yes.  
7 Q. -- whether it's in its  
8 original format or not, it still exists  
9 today in some format. Right?  
10 A. Yes.  
11 Q. And that data is accessible?  
12 MR. TORREGROSSA: Objection  
13 to form.  
14 THE WITNESS: Accessible,  
15 yes. Complex to get to, yes.  
16 BY MR. SMITH:  
17 Q. But you can get to it.  
18 Correct?  
19 A. Right. There would be  
20 challenges getting to some of the  
21 information.  
22 Q. Suppose AstraZeneca were --  
23 let's say -- AstraZeneca has a breast  
24 cancer product, doesn't it? Do you know?

1 Let's say AstraZeneca has Crestor,  
2 correct, as one of its products?  
3 A. Yes.  
4 Q. Do you do any work that  
5 supports Crestor?  
6 A. The systems support Crestor  
7 in terms of the usage and the needs of  
8 the business.  
9 Q. If AstraZeneca decided to  
10 sell Crestor to another drug company,  
11 would they package up all of the  
12 information, all of the data about  
13 Crestor and give that to the purchaser of  
14 the drug?  
15 MR. TORREGROSSA: Objection  
16 to form. We have real scope  
17 problems here, but I'll allow him  
18 to answer. It's hypothetical.  
19 THE WITNESS: I could not  
20 speak of what the business would  
21 require on a termination if we did  
22 something like you said there.  
23 BY MR. SMITH:  
24 Q. Have you ever been involved

1 in the purchase or sale of a drug product  
2 from the technical side?  
3 MR. TORREGROSSA: Objection.  
4 Compound.  
5 THE WITNESS: I have not  
6 been involved in the purchase or  
7 sale -- explain the question, I'm  
8 sorry.  
9 BY MR. SMITH:  
10 Q. If AstraZeneca either  
11 purchased a line, a drug product, took  
12 over the -- added it to their line and  
13 they're going to start selling a new drug  
14 product they bought from a drug company,  
15 or if on the other hand AstraZeneca  
16 decided to sell a product to another  
17 company and they were going to take over  
18 selling it.  
19 A. I have not been involved in  
20 the sale of a product nor the purchase or  
21 any information it would require.  
22 Q. If AstraZeneca decided to  
23 sell Crestor, would you or some person or  
24 people in the IS department be able to

1 collect all of the data regarding that  
2 product so that it could be given to the  
3 purchaser?  
4 A. If we were requested to  
5 collect that kind of information, we  
6 could be requested to do that, and it  
7 would -- I'm sitting here thinking that  
8 would be rather cumbersome in itself as  
9 there's a lot of information and the  
10 databases are very large in size. It  
11 would be a goodly amount of effort to  
12 pull that information out especially when  
13 you talk about one product like Crestor.  
14 Q. Or Seroquel, pick any  
15 product.  
16 MR. TORREGROSSA: Objection  
17 to form.  
18 BY MR. SMITH:  
19 Q. Is there anything special  
20 about Seroquel?  
21 A. Well, the data is stored in  
22 the databases. It's not necessarily  
23 segmented by product in each table. It's  
24 the information stored in it. So you

1 have a lot of complexities around making  
2 sure you pull the right information.

3 Again, hypothetical example  
4 of Crestor, if that were to be sold, we  
5 would have to work diligently to ensure  
6 that what we were providing was related  
7 to Crestor, but also very much make sure  
8 we weren't providing anything but  
9 Crestor. Obviously we wouldn't want to  
10 do that with the information.

11 Most of these systems are  
12 very large and complex, so you would have  
13 to have a definite -- a certain amount of  
14 effort to go in there. I would say it  
15 would be -- I would say several months  
16 to -- longer than several months, to put  
17 that kind of project together and pull  
18 that information out of there, it would  
19 be more closer to six. Just off the top  
20 of my head.

21 Q. So it's really a function of  
22 time, then, to do something like that.  
23 Right?

24 MR. TORREGROSSA: Objection

1 BY MR. SMITH:

2 Q. Back to the division of the  
3 department prior to 2006, you were in  
4 charge of the sales, BIS Sales, and who  
5 was in charge of the other division, the  
6 Marketing Business Information? Who  
7 would have been in charge of that side of  
8 BIS prior to 2006?

9 A. The leader of that  
10 organization would have been Matt Pammer.

11 Q. What is his position today?

12 A. He's the senior director of  
13 Commercial Information Services and  
14 Solutions, my group.

15 Q. So he's one of your  
16 supervisors?

17 A. Yes. He would be -- it was  
18 talked about yesterday. He is my  
19 director's boss.

20 Q. Back to ICON, would there be  
21 a data map or an ERD for ICON?

22 A. Yes.

23 Q. How long -- if I asked you  
24 to get that for me, how long would it

1 to form. Mischaracterizes  
2 testimony.

3 THE WITNESS: It's a  
4 function of knowledge and time.  
5 You would have to understand the  
6 intricacies of all these  
7 databases, and be able to study  
8 and make sure that you understand  
9 that. It would take time to  
10 actually do the work which also  
11 has to be fit in with the work you  
12 are supposed to do to keep the  
13 normal business running. And it  
14 would be the time factor of -- it  
15 would take resources to go and  
16 actually make sure it's accurate.

17 BY MR. SMITH:

18 Q. That three to six month time  
19 effort, would that apply if we said  
20 Seroquel instead of Crestor?

21 MR. TORREGROSSA: Objection  
22 to form.

23 THE WITNESS: I would say  
24 the same for any.

1 take to get that for me?

2 MR. TORREGROSSA: Objection  
3 to form.

4 THE WITNESS: For that piece  
5 of information, it would have to  
6 be -- when I say it's available,  
7 you can generate it with tools.  
8 It would have to be generated,  
9 requested through this request  
10 process. Prioritized for somebody  
11 to do the work. Not having done  
12 that, I would say in my current  
13 environment, if I were to call  
14 Jayne Tomforde, I would think she  
15 would probably suggest two weeks.  
16 That's just the mapping.

17 BY MR. SMITH:

18 Q. The ERD, then, shows the  
19 relationships between the tables.  
20 Correct?

21 A. Right. As you said, it's a  
22 map.

23 Q. It's a map of the fields and  
24 the tables?



1 A. Yes.  
 2 Q. Digressing for a second to,  
 3 let's say, Touchstone, I believe you said  
 4 there were about 3,000 tables in  
 5 Touchstone, something like that. Is that  
 6 correct?  
 7 A. Yes.  
 8 Q. And Touchstone is used for  
 9 all of AstraZeneca's drug products, not  
 10 just Seroquel?  
 11 A. Touchstone is used for the  
 12 products that are promoted by our sales  
 13 force, sold by our sales force.  
 14 Q. And which products are  
 15 those?  
 16 A. Let's see. Seroquel.  
 17 Crestor. Nexium. I may not get every  
 18 one.  
 19 Q. It would be sufficient if  
 20 you say there are others.  
 21 A. There are others. I'll  
 22 throw Arimidex out there.  
 23 Q. So if you have 3,000 tables,  
 24 is it 3,000 tables for each drug product

1 Q. When you say "data  
 2 dictionary," is that the same as the data  
 3 map or is that something different?  
 4 A. The map is the picture. The  
 5 dictionary is the information about the  
 6 tables.  
 7 Q. So for each system that you  
 8 have, you can provide me with a data map  
 9 and a data dictionary?  
 10 MR. TORREGROSSA: Objection  
 11 to form, to the extent you are  
 12 suggesting we will produce it to  
 13 you, but you can answer.  
 14 THE WITNESS: I'm looking.  
 15 MR. TORREGROSSA: While he  
 16 does that, can I have the question  
 17 back?  
 18 - - -  
 19 (The court reporter read the  
 20 pertinent part of the record.)  
 21 - - -  
 22 THE WITNESS: I believe for  
 23 most of the systems on here, we  
 24 could produce that information.

1 or is it only a portion of those tables  
 2 are for Crestor and a portion of those  
 3 tables are for Nexium and a portion of  
 4 those tables are for Seroquel?  
 5 A. A portion is -- when you say  
 6 "portion," I'm cautious. There are  
 7 definitely tables that are used for  
 8 certain functionality that would hold  
 9 certain information.  
 10 Q. So some tables would be used  
 11 for all the drug products you are  
 12 involved with?  
 13 A. Correct.  
 14 Q. And some tables would be  
 15 exclusive to a particular drug product?  
 16 A. Actually I would say no.  
 17 This is a -- Touchstone is built on the  
 18 Siebel SFA. It is built to cover  
 19 multiple products within a configuration.  
 20 So there's not -- I would have to check  
 21 the data dictionary to verify. But I  
 22 would believe, without looking at that,  
 23 that there would not be a table dedicated  
 24 to a single product.

1 BY MR. SMITH:  
 2 Q. Would you also be able to  
 3 produce a diagram that showed information  
 4 flow to other systems, showed sources and  
 5 also information flow to other systems?  
 6 MR. TORREGROSSA: Objection  
 7 to form.  
 8 THE WITNESS: I don't know  
 9 if I could do that.  
 10 BY MR. SMITH:  
 11 Q. Who is the database  
 12 administrator or who was the database  
 13 administrator for ICON?  
 14 A. I believe it would have been  
 15 Tom McCarthy, who is the DBA for the MACS  
 16 system. However -- I believe that's it.  
 17 I'm not 100 percent sure.  
 18 Q. Do you think he would be the  
 19 person with the most knowledge about ICON  
 20 today?  
 21 A. If asked that question, yes.  
 22 He's one of our DBAs. There's a couple.  
 23 Q. We talked about business  
 24 analyst yesterday within the IS division.

1 Did you have a different name or term for  
2 that person, the person who heads  
3 collection of system requirements from  
4 the business owner?

5 A. Yes. I -- when you were  
6 asking that question, I was translating  
7 that -- business analyst to business  
8 consultant.

9 Q. Business consultant. Okay.  
10 I'll use your term then. Who would have  
11 been the business consultant for ICON?

12 A. I'm trying -- it's a --  
13 prior to our reorganization, the roles  
14 were not as clear. So that role may have  
15 been fulfilled by Holly Branham.

16 Q. And who would have been the  
17 business owner of ICON?

18 A. At that time, I could not  
19 recall. I know today -- the person we  
20 spoke of yesterday was Grant Andes. But  
21 I don't know, I could not recall who the  
22 owner would have been prior to Grant.

23 Q. What would have been the  
24 data sources for ICON?

1 within the system itself, my  
2 understanding would be no.

3 Q. Would there have been any  
4 scripts in the ICON system?

5 MR. TORREGROSSA: Objection  
6 to form.

7 THE WITNESS: Can you  
8 describe "scripts," please?

9 BY MR. SMITH:

10 Q. Something for the -- a  
11 protocol or procedure for the call  
12 operator to follow in handling the calls,  
13 in speaking with people.

14 A. What I understand about ICON  
15 is it allows you to do the data entry  
16 based on the call you receive.

17 Specifically if it was a script, I'm not  
18 familiar with that, if it was within the  
19 system itself or if it was a training  
20 document.

21 Q. Can you give me examples of  
22 the types of fields that were contained  
23 in the ICON system?

24 A. Date. Caller, if

1 A. Similar to MACS, it held the  
2 same type of information. It would have  
3 had the entry by the call center and any  
4 configuration to allow that entry.

5 Q. Right. Would there also  
6 have been sources for knowledge that  
7 would be accessible to the IC people?

8 MR. TORREGROSSA: Objection  
9 to form.

10 THE WITNESS: Can you  
11 explain that?

12 BY MR. SMITH:

13 Q. Medical knowledge, let's  
14 say, labeling, those sorts of things?

15 MR. TORREGROSSA: Objection  
16 to form.

17 THE WITNESS: Are you saying  
18 training documentation?

19 BY MR. SMITH:

20 Q. That could be, too. If it  
21 somehow would show up in the ICON system,  
22 do you know if there was any marketing  
23 training information in the ICON system?

24 A. From that perspective,

1 identified. Notes about that interaction  
2 with the customer. And the product area  
3 discussed.

4 Q. Were the notes section, is  
5 that a free form field?

6 A. My understanding is yes.

7 MR. TORREGROSSA: I'm sorry,  
8 I didn't catch that. Was that a  
9 yes?

10 THE WITNESS: Yes.

11 BY MR. SMITH:

12 Q. Was there a maximum size for  
13 the field?

14 A. I would have to -- I would  
15 not know that answer right off the top.  
16 You would have to consult the data  
17 dictionary.

18 Q. In the MACS system, is there  
19 a similar field for notes from the  
20 caller?

21 A. Yes, there is.

22 Q. Is it also a free form  
23 field?

24 A. Yes, it is.

1 Q. Do you know the ICON system  
2 had some provision for handling an  
3 adverse event report?

4 A. Similar to MACS, the adverse  
5 event would have been taken by the call  
6 center and provided to the drug safety  
7 organization to manage.

8 Q. Would that have been -- how  
9 would that have been transmitted to drug  
10 safety?

11 A. When ICON was in operation,  
12 they may have used a form, would be my  
13 best understanding at this time.

14 Q. They would send a piece of  
15 paper over to drug safety?

16 A. I believe there would have  
17 been a form that may have been used with  
18 Outlook. I'm not quite sure if they  
19 would be able to send that through from  
20 system to system.

21 Q. Do you think they had the  
22 capability of using e-mail to send that  
23 communication to safety?

24 A. I believe it would have been

1 answer if you have knowledge.  
2 THE WITNESS: As you asked  
3 before, I believe they would  
4 have -- it may have. I'm not  
5 absolutely sure. I know it was  
6 used to collect the information,  
7 and we could pull that explicitly  
8 in AE. Again, they had to provide  
9 that to drug safety and that would  
10 be the record of it.

11 BY MR. SMITH:

12 Q. Do you recall whether there  
13 was an online form that was filled in for  
14 the adverse event?

15 MR. TORREGROSSA: Same  
16 objection.

17 THE WITNESS: Within ICON, I  
18 would suspect similar to how  
19 salesmen have filled out a form  
20 that would have been based on  
21 Outlook.

22 BY MR. SMITH:

23 Q. How would that work?

24 MR. TORREGROSSA: Objection

1 a form. They certainly could have sent  
2 one to drug safety, but I believe the  
3 policy would be to use the form.

4 Q. Do you know if there was any  
5 form of management within ICON to track  
6 these adverse event reports?

7 A. There may be. My  
8 understanding is the AE system, the drug  
9 safety is the system where that is all  
10 tracked and followed through with.

11 Q. Would people at safety have  
12 the ability to access the ICON system  
13 themselves?

14 A. I do not believe the safety  
15 organization accessed the ICON system.

16 Q. When the adverse event  
17 reports were filled out, were they filled  
18 out within the ICON system so that there  
19 was a record of it within the system?

20 MR. TORREGROSSA: Objection.

21 Scope. And I think we're blurring  
22 the lines of where Mr. Draper  
23 comes in and where Mr. Dowling's  
24 testimony stops, but you can

1 to form.

2 THE WITNESS: They would  
3 pull the form up, fill it out and  
4 it would automatically be sent to  
5 the drug safety organization.

6 BY MR. SMITH:

7 Q. You think that -- that is  
8 different from what I understood your  
9 earlier testimony to be, so --

10 A. I'm --

11 MR. TORREGROSSA: Let him  
12 ask the question first.

13 BY MR. SMITH:

14 Q. Are you saying now that  
15 within ICON there was a way to fill out a  
16 form on line and use Outlook to send it  
17 to safety, drug safety?

18 MR. TORREGROSSA: Objection  
19 to form.

20 THE WITNESS: I'm sorry,  
21 What I'm saying is if they used  
22 the form, I believe it would have  
23 been similar to how sales would  
24 have done it, which they use a

1 form in Outlook.  
 2 BY MR. SMITH:  
 3 Q. Okay. You're saying if they  
 4 did it, it would have been like that?  
 5 A. Yes.  
 6 Q. But you're not sure whether  
 7 they did it or not?  
 8 A. Right.  
 9 MR. TORREGROSSA: Some of  
 10 these answers, Mr. Smith, I think  
 11 we can provide you through the  
 12 deposition of Darryl Draper.  
 13 BY MR. SMITH:  
 14 Q. Who is the vendor for ICON?  
 15 A. I believe ICON was built  
 16 in-house.  
 17 Q. Do you know if there was  
 18 documentation pertaining to ICON?  
 19 MR. TORREGROSSA: Objection  
 20 to form. Vague. Go ahead.  
 21 THE WITNESS: There is  
 22 documentation for ICON.  
 23 BY MR. SMITH:  
 24 Q. Could you provide copies of

1 of inception, but it did exist prior to  
 2 the merger.  
 3 Q. And it was changed over to  
 4 MACS when?  
 5 A. It was changed over to MACS  
 6 in April 2004.  
 7 Q. Was data in the ICON system  
 8 migrated to MACS?  
 9 A. The call records were not.  
 10 The contact information was.  
 11 Q. And what type of database  
 12 was ICON?  
 13 A. Oracle.  
 14 Q. And where was the server?  
 15 A. It would have been  
 16 Southbury, Connecticut. The AstraZeneca  
 17 data center.  
 18 Q. Let's turn now to the  
 19 pricing database. Is that a database  
 20 that IS provided support for?  
 21 MR. TORREGROSSA: The  
 22 pricing database?  
 23 BY MR. SMITH:  
 24 Q. Is there a pricing database?

1 that documentation now?  
 2 MR. TORREGROSSA: Right now  
 3 to you?  
 4 MR. SMITH: No.  
 5 BY MR. SMITH:  
 6 Q. Now as in currently?  
 7 MR. TORREGROSSA: Objection.  
 8 BY MR. SMITH:  
 9 Q. In 2007, let's put it that  
 10 way?  
 11 MR. TORREGROSSA: Objection  
 12 to the extent you're suggesting we  
 13 will produce them.  
 14 MR. SMITH: We wouldn't want  
 15 to suggest that you produce  
 16 anything.  
 17 THE WITNESS: I believe the  
 18 documentation would exist and we  
 19 would be able to -- it would be  
 20 available.  
 21 BY MR. SMITH:  
 22 Q. And what was the timespan  
 23 for ICON?  
 24 A. I don't know the exact date

1 MR. TORREGROSSA: Objection  
 2 to form.  
 3 THE WITNESS: There is a  
 4 pricing tool.  
 5 BY MR. SMITH:  
 6 Q. It's a tool. Is there a  
 7 collection of data associated with that  
 8 tool?  
 9 MR. TORREGROSSA: Same  
 10 objection.  
 11 THE WITNESS: Yes. There  
 12 would be data, yes.  
 13 BY MR. SMITH:  
 14 Q. Is there a name for this  
 15 tool?  
 16 A. I believe the name would be  
 17 Pricing.  
 18 Q. Does the name or term or  
 19 acronym AMOS, A-M-O-S, mean anything to  
 20 you?  
 21 A. Yes, it's one of the  
 22 databases listed on the document here in  
 23 front of me.  
 24 Q. Does it have anything to do